Targeting KRAS-Mutated NSCLC: Novel TKIs and Beyond
Clinical cancer research : an official journal of the American Association for Cancer Research（2023）
Abstract
KRAS-mutated non-small cell lung cancer (NSCLC) is the most common genetically altered subtype of NSCLC, yet targeted therapies remain limited. Multiple studies have investigated combinations of MEK inhibitors with chemotherapy without success. Here we discuss these studies and novel approaches to targeting KRASmutated NSCLC.
MoreTranslated text
Key words
nsclc,novel tkis,<i>kras</i>-mutated
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined